NAPROXEN SODIUM CAPLETS TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
31-01-2012
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
NAPROXEN SODIUM
Beschikbaar vanaf:
VITA HEALTH PRODUCTS INC
ATC-code:
M01AE02
INN (Algemene Internationale Benaming):
NAPROXEN
Dosering:
220MG
farmaceutische vorm:
TABLET
Samenstelling:
NAPROXEN SODIUM 220MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100
Prescription-type:
OTC
Therapeutisch gebied:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0113934003; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2012-01-30
Productkenmerken
_Page 1 of 35_
PRODUCT MONOGRAPH
NAPROXEN SODIUM TABLETS
NAPROXEN SODIUM CAPLETS
NAPROXEN SODIUM TABLETS USP, 220 MG
Non-steroidal anti-inflammatory drug
Analgesic, Antipyretic
Vita Health Products Inc.
150 Beghin Avenue, Winnipeg
Manitoba, Canada R2J 3W2
Date of Preparation:
January 26, 2012
Control No.: 134246
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.............................................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
6
DRUG INTERACTIONS
.........................................................................................................................
9
DOSAGE AND ADMINISTRATION
...................................................................................................11
OVERDOSAGE
.....................................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................12
STORAGE AND STABILITY
...............................................................................................................13
SPECIAL HANDLING INSTRUCTIONS
............................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................................14
PART II:
Lees het volledige document
